ArticleCureus2026
A Single Teaching Hospital Experience With Absorbable LATERA Implant for Nasal Valve Collapse.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNasal valve collapse (NVC) is a common cause of nasal obstruction that significantly impairs quality of life (QoL), which is traditionally treated via functional rhinoplasty. There is, however, no consensus on the best management for NVC. This paper describes the experience of a single district centre using the LATERA implant (Stryker, Kalamazoo, MI, USA) to treat NVC by evaluating its efficacy and safety. Complications and patient satisfaction were evaluated as secondary outcomes.
methodsA prospective study was conducted between 2022 and 2025. Eligible adults were recruited to undergo LATERA implant placement. The primary outcome of efficacy and safety of the LATERA implant was evaluated via the change in the Functional Rhinoplasty Outcome Inventory-17 (FROI-17) scores from baseline to six months post-procedure.
resultsA significant improvement in FROI-17 scores was observed in 90.9% (n=20) of patients, with a mean score decrease of 38.5 points (p<0.01). No major complications, such as infection or implant extrusion, were recorded.
conclusionThe LATERA implant is a safe and effective intervention for NVC, showing a high success rate in significantly improving procedure-specific QoL in our single-centre study. These findings support its role as a valuable minimally invasive option, although further detailed comparative studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.